YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW
YD Bio Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$6.12+0.20 (+3.38%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
YD Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Medical Laboratories companies for comparison
Valuation
| Measure | YD Bio | Industry median |
|---|---|---|
| Market Cap | $433.23M | $1.07B |
| Enterprise Value | $430.57M | $1.35B |
| PS Ratio | 725.90 | 1.63 |
| PB Ratio | 96.83 | 3.19 |
| P/TBV Ratio | 216.59 | 4.88 |
Enterprise value
| Measure | YD Bio | Industry median |
|---|---|---|
| EV / Sales | 721.44 | 1.78 |
Income (trailing twelve months)
| Measure | YD Bio | Industry median |
|---|---|---|
| Revenue | $596.82K | $543.94M |
| Gross Profit | $167.41K | $162.51M |
| Operating Income | -$5.27M | -$1.92M |
| Pretax Income | -$8.31M | -$575.82K |
| Net Income | -$8.31M | -$1.32M |
| EBITDA | -$5.27M | -$29.24K |
| EPS (Diluted) | -$0.12 | -$0.02 |
Margins
| Measure | YD Bio | Industry median |
|---|---|---|
| Gross Margin | 28.1% | 32.7% |
| Operating Margin | -883.3% | -4.46% |
| Pretax Margin | -1392.9% | 1.47% |
| Profit Margin | -1392.6% | -3.18% |
| EBITDA Margin | -883.3% | 2.41% |
| FCF Margin | -1346.6% | 3.11% |
Returns
| Measure | YD Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -173.8% | 0.49% |
| Return on Assets (ROA) | -104.5% | -3.06% |
| Return on Invested Capital (ROIC) | -129.5% | 1.25% |
| Return on Capital Employed (ROCE) | -58.6% | -2.29% |
Growth
| Measure | YD Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.9% | 7.11% |
Balance sheet
| Measure | YD Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.66M | $47.58M |
| Net Cash (Debt) | $2.66M | $217.65K |
| Net Cash Per Share | $0.04 | $0.01 |
| Equity (Book Value) | $4.47M | $189.59M |
| Book Value Per Share | $0.06 | $3.32 |
| Tangible Book Value | $2.00M | $1.72M |
| Working Capital | $4.52M | $29.77M |
Financial position
| Measure | YD Bio | Industry median |
|---|---|---|
| Current Ratio | 5.23 | 1.41 |
| Quick Ratio | 2.70 | 0.97 |
Cash flow (trailing twelve months)
| Measure | YD Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.60M | $1.28M |
| Capital Expenditures | -$1.44M | -$16.47M |
| Free Cash Flow | -$8.04M | $23.23M |
| FCF Per Share | -$0.11 | $0.37 |
Efficiency
| Measure | YD Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.83 |
| Inventory Turnover | 0.23 | 11.36 |
| Revenue Per Employee | $45.91K | $218.24K |
| Profits Per Employee | -$639.33K | -$5.96K |
| Employee Count | 13 | 897 |
Dividends and yields
| Measure | YD Bio | Industry median |
|---|---|---|
| Earnings Yield | -1.92% | -1.25% |
| FCF Yield | -1.86% | 1.43% |
| Buyback Yield | -3.05% | 0.25% |
| Shareholder Yield | -3.05% | 0.60% |
Shares
| Measure | YD Bio | Industry median |
|---|---|---|
| Shares Outstanding | 70,789,300 | 58,609,450 |
| Shares Change (YoY) | 3.07% | 2.64% |
| Float | 5,087,970 | 34,865,600 |
| Shares Held by Insiders | 92.8% | 16.6% |
Taxes
| Measure | YD Bio | Industry median |
|---|---|---|
| Income Tax | -$1.53K | $671.50K |
Scores
| Measure | YD Bio | Industry median |
|---|---|---|
| Altman Z-Score | 44.91 | 1.98 |
| Piotroski F-Score | 2 | 5 |
Calculated by StockData from YD Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.